|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
US8338368B2
(en)
|
2005-11-07 |
2012-12-25 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
|
WO2007140416A2
(en)
|
2006-05-30 |
2007-12-06 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
|
PT2359808E
(pt)
|
2006-08-09 |
2013-08-28 |
Intarcia Therapeutics Inc |
Sistemas de entrega osmótica e montagens de pistão
|
|
JP6017754B2
(ja)
|
2007-02-15 |
2016-11-02 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルカゴン／ｇｌｐ−１受容体コアゴニスト
|
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
|
EP2217701B9
(en)
|
2007-10-30 |
2015-02-18 |
Indiana University Research and Technology Corporation |
Glucagon antagonists
|
|
CA2702289A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
BRPI0915282A2
(pt)
|
2008-06-17 |
2017-02-07 |
Univ Indiana Res & Tech Corp |
agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
|
|
AU2009327418A1
(en)
|
2008-12-19 |
2010-06-24 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
US9150632B2
(en)
|
2009-06-16 |
2015-10-06 |
Indiana University Research And Technology Corporation |
GIP receptor-active glucagon compounds
|
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
US12203113B2
(en)
|
2009-07-09 |
2025-01-21 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
EP3735944A1
(en)
|
2009-09-28 |
2020-11-11 |
Intarcia Therapeutics, Inc. |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
|
RU2012136450A
(ru)
|
2010-01-27 |
2014-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
|
|
EP2569000B1
(en)
|
2010-05-13 |
2017-09-27 |
Indiana University Research and Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
|
US9145451B2
(en)
|
2010-05-13 |
2015-09-29 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhbiting G protein coupled receptor activity
|
|
CA2821766A1
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
US10166295B2
(en)
|
2011-06-02 |
2019-01-01 |
Opko Biologics Ltd. |
Pegylated OXM variants
|
|
HRP20181591T1
(hr)
|
2011-06-10 |
2018-11-30 |
Hanmi Science Co., Ltd. |
Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
|
|
AU2012270366C1
(en)
|
2011-06-17 |
2017-07-13 |
Hanmi Science Co., Ltd. |
A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
|
|
BR112013032717A2
(pt)
|
2011-06-22 |
2017-01-24 |
Univ Indiana Res & Tech Corp |
coagonistas do receptor de glucagon/glp-1
|
|
EA031230B1
(ru)
|
2011-06-22 |
2018-12-28 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Агонисты глюкагонового рецептора/glp-1-рецептора
|
|
CA2847246A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
|
JP2015520128A
(ja)
|
2012-04-19 |
2015-07-16 |
オプコ バイオロジクス リミテッド |
長時間作用性オキシントモジュリン変異体とその作製方法
|
|
KR102092025B1
(ko)
|
2012-06-04 |
2020-03-24 |
옵코 바이오로직스 리미티드 |
페길화된 옥신토모둘린 변이체
|
|
RU2015101697A
(ru)
|
2012-06-21 |
2016-08-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, обладающие активностью рецептора gip
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
KR101993393B1
(ko)
*
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
NZ739063A
(en)
|
2012-11-06 |
2019-11-29 |
Hanmi Pharm Ind Co Ltd |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
ES2882890T3
(es)
|
2012-11-20 |
2021-12-03 |
Opko Biologics Ltd |
Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina
|
|
SG10201705097PA
(en)
|
2012-12-21 |
2017-07-28 |
Sanofi Sa |
Functionalized exendin-4 derivatives
|
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
TWI772252B
(zh)
|
2014-09-16 |
2022-08-01 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
WO2016092550A2
(en)
|
2014-12-10 |
2016-06-16 |
Opko Biologics Ltd. |
Methods of producing long acting ctp-modified polypeptides
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
KR102650751B1
(ko)
|
2015-06-03 |
2024-03-22 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
|
WO2016198628A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
|
|
EP3988113A1
(en)
|
2015-06-19 |
2022-04-27 |
OPKO Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
|
TWI669309B
(zh)
|
2015-06-22 |
2019-08-21 |
美商美國禮來大藥廠 |
升糖素及ｇｌｐ－１共激動劑化合物
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
CN109310743A
(zh)
|
2016-05-16 |
2019-02-05 |
因塔西亚制药公司 |
胰高血糖素受体选择性多肽及其使用方法
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
WO2017212494A1
(en)
|
2016-06-09 |
2017-12-14 |
Opko Biologics Ltd. |
Long-acting oxyntomodulin formulation and methods of producing and administering same
|
|
BR112019000610A2
(pt)
|
2016-07-11 |
2019-07-02 |
Opko Biologics Ltd |
fator vii de coagulação de longa ação e métodos de produção do mesmo
|
|
AR110299A1
(es)
|
2016-12-02 |
2019-03-13 |
Sanofi Sa |
Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
|
|
AU2018206539A1
(en)
|
2017-01-03 |
2019-07-18 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
|
CN108299553B
(zh)
*
|
2017-01-13 |
2021-07-16 |
博瑞生物医药（苏州）股份有限公司 |
胃泌酸调节素修饰物
|
|
KR20200135618A
(ko)
*
|
2019-05-23 |
2020-12-03 |
㈜ 디앤디파마텍 |
폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
|
|
KR101990075B1
(ko)
*
|
2018-07-19 |
2019-06-18 |
㈜ 디앤디파마텍 |
폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
|
|
JP2021530533A
(ja)
|
2018-07-19 |
2021-11-11 |
ディーアンドディー ファーマテック インコーポレイテッド |
ポリペプチドを含む医薬組成物
|
|
US12441776B2
(en)
|
2018-11-30 |
2025-10-14 |
Eirgen Pharma Ltd. |
Oxyntomodulin peptide analog formulations
|
|
WO2025169190A2
(en)
|
2024-02-06 |
2025-08-14 |
Opko Biologics Ltd. |
Modified oxyntomodulin and methods of use thereof
|